JP2022546577A - Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ） - Google Patents

Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ） Download PDF

Info

Publication number
JP2022546577A
JP2022546577A JP2022514522A JP2022514522A JP2022546577A JP 2022546577 A JP2022546577 A JP 2022546577A JP 2022514522 A JP2022514522 A JP 2022514522A JP 2022514522 A JP2022514522 A JP 2022514522A JP 2022546577 A JP2022546577 A JP 2022546577A
Authority
JP
Japan
Prior art keywords
region
seq
dar
cells
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022514522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546577A5 (https=
JPWO2021046445A5 (https=
Inventor
ヘンリー ホンジュン ジ，
ウェンジョン グオ，
ヤンリャン ジャン，
ベイ ベイ ディン，
ガナー エフ． カウフマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2022546577A publication Critical patent/JP2022546577A/ja
Publication of JP2022546577A5 publication Critical patent/JP2022546577A5/ja
Publication of JPWO2021046445A5 publication Critical patent/JPWO2021046445A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022514522A 2019-09-05 2020-09-04 Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ） Pending JP2022546577A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962896190P 2019-09-05 2019-09-05
US62/896,190 2019-09-05
US201962896990P 2019-09-06 2019-09-06
US62/896,990 2019-09-06
US201962910341P 2019-10-03 2019-10-03
US62/910,341 2019-10-03
US201962943069P 2019-12-03 2019-12-03
US62/943,069 2019-12-03
US202063030145P 2020-05-26 2020-05-26
US63/030,145 2020-05-26
PCT/US2020/049538 WO2021046445A1 (en) 2019-09-05 2020-09-04 Dimeric antigen receptors (dar) that bind bcma

Publications (3)

Publication Number Publication Date
JP2022546577A true JP2022546577A (ja) 2022-11-04
JP2022546577A5 JP2022546577A5 (https=) 2023-09-11
JPWO2021046445A5 JPWO2021046445A5 (https=) 2023-09-11

Family

ID=74852154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514522A Pending JP2022546577A (ja) 2019-09-05 2020-09-04 Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ）

Country Status (10)

Country Link
US (1) US20220251168A1 (https=)
EP (1) EP4025227A4 (https=)
JP (1) JP2022546577A (https=)
KR (1) KR20220057598A (https=)
CN (1) CN114650829A (https=)
AU (1) AU2020341712A1 (https=)
CA (1) CA3149867A1 (https=)
IL (1) IL291076A (https=)
MX (1) MX2022002723A (https=)
WO (1) WO2021046445A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202109163YA (en) * 2019-02-26 2021-09-29 Sorrento Therapeutics Inc Antigen binding proteins that bind bcma
EP4139345A1 (en) 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
WO2022226364A2 (en) * 2021-04-23 2022-10-27 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dars) that bind gd2
KR20240051280A (ko) * 2021-09-06 2024-04-19 젠맵 에이/에스 Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
CN116655805B (zh) * 2023-05-31 2024-03-08 四川大学华西医院 一种靶向her2阳性肿瘤的新型car-t细胞及制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517407A (ja) * 2015-05-15 2018-07-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ キメラ抗原受容体組成物
WO2019089969A2 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
JP2021515558A (ja) * 2018-03-09 2021-06-24 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 二量体抗原受容体（ｄａｒ）

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
US11173179B2 (en) * 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
EP3842450A1 (en) * 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
US12195529B2 (en) * 2017-06-21 2025-01-14 Gsbio, Llc Heterodimeric bispecific antibodies
SG11202109163YA (en) * 2019-02-26 2021-09-29 Sorrento Therapeutics Inc Antigen binding proteins that bind bcma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517407A (ja) * 2015-05-15 2018-07-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ キメラ抗原受容体組成物
WO2019089969A2 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
JP2021515558A (ja) * 2018-03-09 2021-06-24 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 二量体抗原受容体（ｄａｒ）

Also Published As

Publication number Publication date
EP4025227A4 (en) 2023-11-01
KR20220057598A (ko) 2022-05-09
MX2022002723A (es) 2022-03-22
CA3149867A1 (en) 2021-03-11
WO2021046445A1 (en) 2021-03-11
CN114650829A (zh) 2022-06-21
EP4025227A1 (en) 2022-07-13
US20220251168A1 (en) 2022-08-11
AU2020341712A1 (en) 2022-03-31
IL291076A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
US20240294639A1 (en) Antigen-binding proteins targeting cd56 and methods of producing thereof
US12180294B2 (en) Dimeric antigen receptors
US20220144960A1 (en) Cd30-binding moieties, chimeric antigen receptors, and uses thereof
US20220251168A1 (en) Dimeric Antigen Receptors (DAR) that Bind BCMA
IL310130A (en) Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
TW202444751A (zh) 重組Ｆｃ域—ＩＬ２變異體多肽及與膜錨定抗原結合多肽的組合療法
US20230061838A1 (en) Dimeric Antigen Receptors (DAR) That Bind CD20
US20230167191A1 (en) Memory Dimeric Antigen Receptors (mDARs)
US20240197881A1 (en) Dimeric Antigen Receptors (DARs) that Bind GD2
CN117545493A (zh) 与gd2结合的二聚体抗原受体（dar）

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241122

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250328